Alpha Centric Advisors LLC Molecular Partners Ag Call Options Transaction History
Alpha Centric Advisors LLC
- $97.4 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MOLN
# of Institutions
6Shares Held
3.58MCall Options Held
0Put Options Held
0-
Suvretta Capital Management, LLC New York, NY2.22MShares$9.62 Million0.44% of portfolio
-
Bvf Inc San Francisco, CA1.35MShares$5.86 Million0.24% of portfolio
-
Ubs Group Ag6.87KShares$29,7550.0% of portfolio
-
Morgan Stanley New York, NY367Shares$1,5890.0% of portfolio
-
Rhumbline Advisers Boston, MA269Shares$1,1640.0% of portfolio
About MOLECULAR PARTNERS AG
- Ticker MOLN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,514,000
- Market Cap $141M
- Description
- Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, ...